Special
Shaping the Future of the Beauty Industry: Can Skin Microbiome Products Succeed Cosmetics?
2021-10-25
Scientists Identify Antidotes To Overcome Collateral Damage of Antibiotics on Gut Microbiota
2021-10-20
Biogen’s ALS Drug Fails to Attain Primary Endpoint but Offers Hope With Secondary Outcomes
2021-10-18
Apnimed’s Oral Drug for Obstructive Sleep Apnea Registers Encouraging Outcomes in Two Phase 2 Trials
2021-10-14
Takeda Inks $3.6 Billion Deal with Poseida to Advance Non-Viral Gene Therapies and Overcome Safety Issues
2021-10-13
Expanding Deals and Investments Underscore Burgeoning Market of Targeted Protein Degradation
2021-10-07
BARDA Exercises $23.8 Million to Support Phase 3 Trial of Vedanta’s Encouraging Microbiome Therapy
2021-10-07
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23